[A21-156] Risankizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V

Last updated 01.03.2022

Project no.:
A21-156

Commission:
Commission awarded on 01.12.2021 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Skin and hair

Indication:

Adult patients with active psoriatic arthritis who have had an inadequate response or who have been intolerant to a prior therapy with disease-modifying antirheumatic drugs (DMARDs)

Result of dossier assessment:
  • Adults with active psoriatic arthritis who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy: added benefit not proven.
  • Adults with active psoriatic arthritis who have had an inadequate response or who have been intolerant to a prior therapy with biologic disease-modifying antirheumatic drugs (bDMARDs): added benefit not proven.
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form